Kornimate/medical-research-clean huggingface dataset:
intravenous vs oral lansoprazole on gastric acid secretion in subjects with erosive esophagitis

Conditions: Esophagitis; Reflux

Summary: the purpose of this study was to compare the pharmacodynamics of intravenous (iv) lansoprazole to oral lansoprazole capsules, once daily (qd), in participants with erosive esophagitis.

phase 2, open label, multi-center, 2-period study to compare the pharmacodynamics of iv lansoprazole 30 mg to oral lansoprazole 30 mg in subjects with erosive esophagitis (grade \>or= 2)diagnosed by endoscopy.

Eligibility criteria:
inclusion criteria: * subjects were required to have grade 2, 3 or 4 esophageal findings according to the tap grading scale during the pretreatment endoscopy. * subjects must discontinue histamine h2-receptor antagonists, proton pump ® inhibitors, prokinetic agents, antacids and carafate before the first dose of drug and during the study. exclusion criteria: * gastric or duodenal ulcer (a lesion with appreciable depth ≥3 mm) or a hiatal hernia \>5 cm. * subjects could not have a diagnosis of barrett's esophagus (with or without dysplastic changes). * co-existing systemic disease affecting the esophagus, (ie, scleroderma, viral or fungal infection), radiation therapy to the region of the esophagus, or caustic or physiochemical trauma to the esophagus. * current esophageal stricture requiring dilatation. the endoscope had to pass freely into the stomach during endoscopy. any strictures could not have been dilated within 12 weeks before beginning the pretreatment period. * positive h pylori by rapid urease test (clo® test kimberly-clark corporation). * uncontrolled, clinically significant cardiovascular, pulmonary, renal, hepatic, metabolic, gastrointestinal, neurological or endocrine disease or other abnormality (other than the erosive esophagitis disease being studied). * diagnosis of zollinger-ellison syndrome, esophageal varices, symptomatic pancreaticobiliary tract disease, cholecystitis, rheumatoid arthritis, lupus, or malignancy (except basal cell carcinoma).

Keywords: intravenous gastric acid secretion lansoprazole esophagitis reflux
feasibility of a self-management app for people with knee osteoarthritis (oa-aid feasibility study)

Conditions: Knee Osteoarthristis

Summary: in this feasibility trial, an 8-week digital intervention including remote monitoring in patients with knee osteoarthritis (oa) will be tested. the app will provide information on osteoarthritis and recommended treatment for people with knee oa.

in this feasibility study various outcome measures will be assessed to determine whether the app (genus) is viable, practical, and useful. the study will test the feasibility of an 8-week digital intervention including remote monitoring prior to consultation in specialist healthcare. the app consist of information on osteoarthritis and recommended treatment for people with knee oa. a total of 20 patients referred to diakonhjemmet hospital due to knee oa will be recruited to the study. the study will include assessments of technical, operational, clinical, and trial aspects of feasibility. data will be collected through digital questionnaires (through the app or nettskjema), through interviews and from medical records. primary outcome is the feasibility of the app after 8 weeks. additionally, the feasibility of the study process until consultation in specialist healthcare will be assessed. the aim of the app is to improve patients' health literacy and enhance the shared decision-making process between patient and healthcare provider at the consultation in specialist healthcare.

Eligibility criteria:
inclusion criteria: * men and women =\>50 years of age * referred to specialist healthcare for knee oa management exclusion criteria: * received joint replacement or are under consideration for revision in the referred joint * have uncontrolled serious comorbidities * have cognitive dysfunction * are seeking care for trauma conditions or psoriatic/rheumatoid arthritis * unable to understand norwegian * do not have a smartphone

Keywords: osteoarthritis e-health remote care feasibility
interferon gamma induced protein 10 (ip-10) in a clinical decision support protocol in covid-19 patients

Conditions: COVID-19

Summary: the proposed project will pilot incorporation of rapid serial measurements of ip-10 into a cds tool for moderate and severe covid-19 patients. the tool was applied to all comers with confirmed covid-19 diagnosis at a secondary medical center in israel.


Eligibility criteria:
inclusion criteria: * pcr- positive for covid-19 exclusion criteria: * \<18 years of age
comparison of 50% tilt and tuned waveforms in single-coil active can configuration

Conditions: Sudden Cardiac Death

Summary: the purpose of this study is to compare the defibrillation efficacy between the 50/50% tilt biphasic waveform and the tuned biphasic waveform in a single coil active can configuration.

there has been one prospective study that found some benefit of using tuned waveforms over 50/50% tilt waveforms.11 other studies have failed to show much change in defibrillation efficacy with different duration biphasic waveforms. a vast majority of patients in these studies were tested with dual coil leads. although dual coil leads can lower defibrillation thresholds, it is known that dual coil leads can make the lead extraction difficult, lead to venous obstruction and are more prone to failure. results from a recent study showed that that a single coil configuration is adequate in a vast majority of patients when dft testing was performed with tuned waveforms. this makes the use of single-coil leads during icd/ crt-d implants an attractive option. theoretical analysis has shown that difference between the tuned and 50% tilt waveforms is amplified at high impedance levels with tuned waveforms being superior (unpublished). accordingly, this study has been designed to prospectively compare the dft estimates with tuned and 50% tilt waveforms in left-sided, active pectoral defibrillation lead systems when the svc coil has been turned off or is not part of the shocking circuit.

Eligibility criteria:
inclusion criteria: * patient meets standard indication for an icd/ crt-d and will be implanted with an fda approved sjm icd/ crt-d and compatible defibrillation lead system in the left pectoral region. * patient is able to tolerate dft testing. exclusion criteria: * patient has the pulse generator on the right side. * patient is pregnant. * patient is less than 18 years old. * svc coil was turned on during dft testing
enstilar in combination with biologic agents

Conditions: Psoriasis

Summary: patients receiving biologic therapy with 5% or less body surface area will receive enstilar topical foam for 16 weeks.

a two-phase, single center, observational study of 25 subjects to assess 4 weeks of adjunctive therapy of enstilar® qd followed by 12 weeks qd on two consecutive days a week to patients with ≤5% bsa who are receiving biologic therapy for at least 24 weeks

Eligibility criteria:
inclusion criteria: 1. male or female adults ≥ 18 years of age. 2. diagnosis of chronic plaque-type psoriasis. 3. able to give written informed consent prior to performance of any study related procedures. 4. treated with a biologic agent for a minimum of 24 weeks at baseline. 5. plaque-type psoriasis as defined at screening and baseline by bsa ≤ 5%. 6. females of childbearing potential (fcbp) must have a negative pregnancy test at screening and baseline. fcbp who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (iud); tubal ligation; or partner's vasectomy; male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. 7. subject must be in general good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination. exclusion criteria: 1. \>5% body surface area 2. any condition, which would place the subject at unacceptable risk if he/she were to participate in the study. 3. pregnant or breast feeding, or considering becoming pregnant during the study. 4. use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer). 5. use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine). 6. patient used other topical therapies to treat within 2 weeks of the baseline visit (includes, but not limited to, topical corticosteroids, vitamin d analogs, or retinoids). 7. patient received uvb phototherapy within 2 weeks of baseline. 8. patient received puva phototherapy within 4 weeks of baseline. 9. patient has a known hypersensitivity to the excipients of enstilar® as stated in the label.
fulvestrant in hormone refractory prostate cancer

Conditions: Prostatic Neoplasms; Prostate Cancer

Summary: the purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (aipc) or hormone-refractory prostate cancer (hrpc) and who have a rising serum prostate specific antigen (psa).

the purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (aipc) or hormone-refractory prostate cancer (hrpc) and who have a rising serum prostate specific antigen (psa). in vitro studies have shown that fulvestrant downregulates androgen receptor (ar) in lncap cancer cell lines to a significant extent, thereby inhibiting growth of tumor cells. in addition, it is important to emphasize that fulvestrant has also been found to decrease growth of ar-negative prostate cancer cells. these observations provide the rational for using fulvestrant for the treatment of aipc and hrpc.

Eligibility criteria:
inclusion criteria: * must give signed written informed consent * must be of age 18 years or older * histologically confirmed adenocarcinoma of the prostate * must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy * must have had rise in psa despite anti-androgen withdrawal * must exhibit two consecutive rises in psa after the last hormonal manipulation * minimum psa \> 5mg/dl * kps \> 80% * up to one prior chemotherapy treatments allowed * life expectancy of greater than 6 months exclusion criteria: * concomitant hormonal therapy other than an lhrh * noncompliance * platelets less than 100 x 10e9 /l * international normalization ratio (inr) greater than 1.6 * total bilirubin greater than 1.5 x ulrr * alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases * history of bleeding diathesis (ie, disseminated intravascular coagulation \[dic\], clotting factor deficiency) * history of long-term anticoagulant therapy (other than antiplatelet therapy) * history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
adrenal venous sampling via an antecubital approach

Conditions: Hyperaldosteronism; Angiography

Summary: currently, adrenal venous sampling (avs) serves as the gold standard for subtyping of pa. right adrenal vein catheterization is often difficult due to unfavorable anatomy of the vein including small vein size, short length, caudal direction for the transfemoral approach, and rare drainage to the accessory hepatic vein. all of these factors limit the widespread use of this approach. given that the right adrenal vein is angled caudally in most patients, avs via an antecubital approach was performed since january 2012. the purpose of this multicenter retrospective study was to evaluate the safety and feasibility of avs via the antecubital approach.

primary aldosteronism (pa) is recognized as the most common cause of secondary hypertension, with a prevalence of approximately 10% among unselected hypertensive populations. subtype diagnosis is crucial because unilateral primary aldosteronism can be treated by laparoscopic adrenalectomy or open surgery, which may result in a cure or significant improvement of blood pressure, thus decreases the incidence of cardio-cerebrovascular complications. currently, adrenal venous sampling (avs) serves as the gold standard for subtyping of pa. given that the right adrenal vein is angled caudally in most patients, avs via an antecubital approach was performed since january 2012 at the fuwai hospital. so far, there have been more than fifteen hospitals to have some experience on avs via antecubital approach with investigators' helps. the purpose of this multicenter retrospective study was to evaluate the safety and feasibility of avs via the antecubital approach.

Eligibility criteria:
inclusion criteria: * consent of the principal investigator to participate to the data collection of patients with primary aldosteronism underwent avs via antecubital approach exclusion criteria: * refusal of the principal investigator to participate to the avsa study

Keywords: adrenal venous sampling hyperaldosteronism angiography antecubital approach
severe acute respiratory syndrome coronavirus 2 (sars-cov-2) buccal screening evaluation using an rt-pcr assay and a rapid elisa test among symptomatic and asymptomatic patients

Conditions: SARS-CoV-2; COVID-19

Summary: the main objective is to expand screening for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) by evaluating the diagnostic accuracy of the rt-pcr test (cobas® roche, switzerland) and the elisa point of contact testing (portable covid-19 antigen lab® stark, italy) on buccal swab compared to the reference test, the rt-pcr test (cobas® roche, switzerland) on nasopharyngeal swab. secondary objectives * to evaluate the diagnostic accuracy of oral swab rt-pcr and poct relative to the quantitative amplification (ct) values of the np swab rt-pcr assay. * analyze rt-pcr amplification cycle thresholds (ct) and poct diagnostic accuracy as a function of the presence and timing of symptoms. * among symptomatic participants, compare clinical presentations between positive and negative participants on the np swab rt-pcr test. * the rt-pcr test may be imperfectly sensitive, ranging from 71 to 98%3. using a bayesian latent class model, the investigators will assess the true accuracy of poct as it does not require the assumption that any one test or combination of tests is perfect14,15.


Eligibility criteria:
inclusion criteria: * 18+ patient eligible for covid-19 testing in monaco * symptoms suggestive of covid-19 * contact with a confirmed case of covid-19 exclusion criteria: * refusal to participate in the study * preventive screening of professional groups * inability to return to the screening center within 48-72 hours of the first visit.

Keywords: sars-cov-2 poct rt-pcr contact case elisa buccal
effects of acupuncture as adjunctive therapy in patients with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2; Acupuncture

Summary: this study aims to determine the effect of acupuncture as an adjunctive therapy on homeostasis model assessment-insulin resistance (homa-ir) and health-related quality of life (hrqol) in patients with type 2 diabetes mellitus.

this is a randomised, double-blind, placebo controlled and parallel design trial. participants will be randomized to either acupuncture (n=30) or placebo (n=30) using a 1:1 ratio. the permuted blocks with a block size of 2 will be used. both groups will continue with their routine diabetes care. primary outcome of homa-ir will be measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. secondary outcome of hrqol will be measured at the time of recruitment (baseline), after completion of 5 sessions (week 3/4) and 10 sessions (week 7) of the treatment while outcomes of body mass index and waist circumference are measured at the time of recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment. any adverse event will be recorded at every visit. the sequence generation and allocation will remain concealed from the patient and practitioner.

Eligibility criteria:
inclusion criteria: * fasting plasma glucose (fpg) ≥ 7.0 mmol/l \[126 mg/dl\] or hba1c ≥ 6.5%. * subjects have had type 2 diabetes mellitus for more than one year * receive oral anti-diabetic agents on a stable dose over the previous 3 months. exclusion criteria: * under insulin therapy * with other acute or chronic health problems * body mass index (bmi) ≥ 40.0 kg/m² * needle phobia or allergy to adhesive plaster * planning to move out from malaysia within 4 months' * being pregnant, planning for pregnancy or lactating women

Keywords: type 2 diabetes mellitus acupuncture randomized controlled trial
a study to evaluate cln® bodywash as added therapy in eczema patients

Conditions: Eczema; Atopic Dermatitis

Summary: the purpose of this study is to determine if cln bodywash, a novel new gel cleanser formulated with surfactants and preserved with sodium hypochlorite, is effective at decreasing severity, body surface area and itching for patients with atopic dermatitis, or eczema.

staphylococcus aureus colonization and potential infection represent a common clinical finding in patients with atopic dermatitis (ad) and may contribute to exacerbation of the disease. atopic patients are commonly colonized with s. aureus on both lesional and non-lesional skin. antibiotic treatment of clinically infected patients can often improve the bacterial infection as well as reduce the overall severity of ad. more recently, measures to reduce s. aureus colonization have been shown to decrease the clinical severity of atopic dermatitis in patients with clinical signs of secondary bacterial infection of the skin. given the increasing incidence of recurrent skin infections caused by s. aureus, measures such as dilute sodium hypochlorite (bleach) baths have been adopted by many physicians in an effort to decrease infection rates and disease severity in patients with atopic dermatitis, recurrent impetigo, cellulitis, folliculitis, boils and abscesses. there is some controversy in the literature regarding the efficacy of anti-staphylococcal treatments in improving ad in patients without active clinical infection as one review noted limited benefit while another study showed that dilute bleach baths improved ad. bleach baths are widely used in pediatrics and adult medicine. a common regimen consists of adding ½ cup of household bleach into ½ tub of warm bath water, resulting in a 0.009% sodium hypochlorite concentration. (www.bleachbath.com) cln® bodywash contains several common surfactants to clean the skin and 0.006% sodium hypochlorite concentration for preservation, and is further diluted when lathered onto the skin with water. this over the counter product is delivered in a sealed, easy to use dispenser, which can be used in the bath or shower, lathered on and rinsed off after 1-2 minutes of skin contact. cln® bodywash may be a convenient alternative to bleach baths.

Eligibility criteria:
inclusion criteria: * 6 months to 18 years * moderate to severe atopic dermatitis * positive staphylococcus aureus skin culture exclusion criteria: * active clinical infection * on antibiotics in the last 4 weeks * on immunosuppression drug in the last 4 weeks * using bleach bath in the last 2 weeks * able to maintain current regimen

Keywords: eczema atopic dermatitis compromised skin inflamed skin
transcutaneous vagus nerve stimulation as a complementary therapy to exercise in chronic fatigue

Conditions: Chronic Fatigue Syndrome

Summary: chronic fatigue is enhanced by adapted physical activity (apa) programs. patients consulting on st etienne hospital and suffering from fibromyalgia and long covid benefit from a 4-6 week apa program, with 2 sessions per week. while most patients are improved by these exercise-training programs, for some the benefits remain very modest, and patients describe persistent fatigue. the literature unanimously describes the necessity of longer apa protocols (8-12 weeks, 2-3 sessions/week) for fatigue reduction in fibromyalgia and long covid. however, it seems difficult to adhere to an optimal program as described in the literature for these fatigued patients. the investigators want to test a device that would both reduce fatigue and improve recovery between apa sessions, in order to gradually reach the recommendations for apa practice. transcutaneous vagal nerve stimulation (tvns) seems to be a promising approach. thus, combining an apa intervention with a tvns protocol could potentiate the expected and now well-known effect of exercise.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * signature of informed consent * confirmed diagnosis of fibromyalgia or long covid (acr 2016 criteria and persistent symptoms lasting more than 6 months after a positive rt-pcr test, respectively) * persistent fatigue after an exercise rehabilitation program (fss score \> 36) * physical inactivity, i.e. \<150 minutes per week of physical activity exclusion criteria: * pre-existing atrial fibrillation, * left ventricular ejection fraction \<40% * severe heart failure * recent stroke or myocardial infarction (\<6 months) * unilateral or bilateral vagotomy * pregnancy or breastfeeding

Keywords: chronic fatigue transcutaneous vagal nerve stimulation (tvns) adapted physical activity (apa)
the effect of abdominal aortic aneurysm screening on mortality in asian population

Conditions: Aortic Aneurysm, Abdominal

Summary: abdominal aortic aneurysm(aaa) occurs when the infrarenal aorta expands to a maximal diameter of 3.0cm or greater. although aaa may asymptomatic for many years, almost one third eventually rupture if left untreated. several randomized trials showed that ultrasonographic screening for aaa could reduce the frequency of acute operations and aaa-related mortality. however, all of randomized trials were performed in western countries. there was no randomized trials for aaa screening in asian countries. this randomized, controlled trial is to analyze the benefits of screening old population for aaa in korea.

old population, aged from 60 to 85 years, are randomized into two groups; one group is invited for ultrasonographic screening for aaa, and the other acts as age- and sex-matched controls. for screening group, the anterioposterior and transverse diameter of the infrarenal aorta is measured at their maximal sizes. the subsequent surveillance of screened patients is done as follows * aortic diameter less than 3.0cm, no further testing * aaa 3 to 4cm, ultrasonographic follow-up every year * aaa 4 to 5cm, ultrasonographic follow-up every 6 months * aaa greater than 5cm, referral to a vascular surgeon for control group, the information for any causes of death is collected every year.

Eligibility criteria:
inclusion criteria: * all men aged 60 to 85 years * women aged 60 to 85 years with cardiovascular risk factors such as hypertension, hyperlipidemia, peripheral arterial occlusive disease, coronary artery disease, cerebrovascular attack. * men and women older than 50 years with a family history of aaa exclusion criteria: * people who was diagnosed with aaa * people who underwent aneurysm repair such as open aneurysm repair or endovascular aneurysm repair * people who underwent abdominal aortic surgery such as aortobifemoral bypass * people whose life expectancy is less than 2 years * people who appear unfit for repair of aaa * people who do not agree with this study

Keywords: aortic aneurysm, abdominal screening mortality